Oncopeptides launches Oslo window-of-opportunity glioblastoma study after regulatory clearance

• Oncopeptides flagged a move into glioblastoma, citing swift regulatory clearance to start a Window-of-Opportunity clinical study in Oslo.
• Preclinical and translational glioblastoma findings were accepted for poster presentation at the EANO 2026 congress in Rome on Sept. 24-27.
• Results have not yet been presented; one poster was nominated for an EANO 2026 Poster Award.
• Data indicate its next-generation peptide-drug conjugates can reach the brain, attack tumors through multiple mechanisms, and counter key resistance pathways.
• The program broadens the platform beyond multiple myeloma, where Pepaxti remains the lead commercial focus.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncopeptides AB published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.